Pediatric Oncology Program
Pediatric Oncology Program
Pediatric Oncology Program
Pediatric Neuro-Oncology Program
Pediatric Thrombosis Program
The findings from recent research studies in pediatric cancer offer hope for drug development.
Pediatric Sarcoma Program
Pediatric Cancer Clinical Trials
At Mays Cancer Center, you can access exceptional surgical expertise for complex conditions affecting the brain and spine in babies and children. Our team’s fellowship-trained pediatric surgeon performs sophisticated surgeries in delicate areas. Our deep experience helps us remove brain and spinal tumors safely, with a high degree of precision.
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Radiation therapy can be a useful tool in treating childhood cancers. At Mays Cancer Center, our team includes radiation oncologists with expertise in the unique needs of pediatric patients. We treat children from infancy to adulthood, using leading therapies that destroy cancer cells with exceptional precision. Our care always focuses on a child’s comfort, safety and long-term health.
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.